The Back Pain Consortium (BACPAC) Research Program: Cover.
The Back Pain Consortium (BACPAC) Research Program: Cover.
复制标题
背痛联盟 (BACPAC) 研究计划：封面。
DOI：
10.1093/pm/pnac199
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Criswell,LindseyA
中科院分区：
文献类型：
--
作者：
Carter,RobertH;Criswell,LindseyA
背部疼痛是常见的，使人虚弱，经常被阿片类药物使用障碍的人列为一个促成因素。研究改善慢性背痛患者的预后是一项重要的需要，这既是研究本身，也是我们努力应对目前阿片类药物过量死亡的国家危机的一部分。出于这些原因，背痛联盟(BACPAC)研究计划被启动，作为NIH帮助结束成瘾长期倡议的一部分，或NIH Hear倡议SM。BACPAC旨在采取全面的方法来了解和治疗背痛。这包括在发现层面上的研究，这将提高我们对背痛机制的理解，目标是开发一个包含所有关键因素的理论模型。在翻译层面，bacpac正在支持可用于理解或治疗背痛的新技术的开发，例如传感器或虚拟现实耳机，这些技术目前正在进入临床测试。最后，联盟范围内的临床研究，即评估脊柱治疗的生物标记物试验(BEST)，不仅旨在确定一种或另一种干预措施总体上是否更好，而且根据患者的表型和心理社会背景，为他们匹配最好的治疗，包括顺序或附加干预。本期《疼痛医学》包含了有关所有这些努力的重要信息。我们作为国家关节炎和肌肉骨骼与皮肤病研究所的代表，感谢来自国家关节炎和肌肉骨骼与皮肤病研究所和其他机构、中心和办公室的工作人员，这些机构、中心和办公室(国家老龄研究所、国家儿童健康与人类发展研究所、国家药物滥用研究所、国家精神健康研究所、国家神经疾病和中风研究所、国家护理研究所、国家少数民族健康和差异研究所、国家补充和综合健康中心、行为和社会科学研究办公室、妇女健康研究办公室)都加入了这一努力。我们特别向所有勤奋合作、推动背痛研究向前发展的研究人员致敬。尽管发生了新冠肺炎疫情，但该项目仍得以维持，这主要是通过调查人员保持沟通渠道的努力。情况也发生了变化，出现了新的
Back pain is common, debilitating, and frequently cited as a contributing factor by those with opioid use disorder. Research to improve outcomes for those with chronic back pain is an important need, both in itself and as part of our efforts to combat the current national crisis in deaths from opioid overdose. For these reasons, the Back Pain Consortium (BACPAC) Research Program was launched as part of the NIH’s Helping to End Addiction Long-TermSM Initiative, or NIH HEAL InitiativeSM.BACPAC is designed to take a comprehensive approach to understanding and treating back pain. This includes studies at a discovery level that will improve our understanding of mechanisms of back pain, with the goal of developing a theoretical model that incorporates all the key contributors. At the translational level, BACPAC is supporting development of new technologies that can be used to understand or treat back pain, such as sensors or virtual reality headsets, which are now moving into clinical testing. Finally, the consortium-wide clinical study, the Biomarkers for Evaluating Spine Treatments Trial (BEST), is designed not only to determine whether one or another intervention is better overall, but to match patients, on the basis of their phenotypes and psychosocial contexts, to the best treatment for them, including sequential or additive interventions. This issue of Pain Medicine contains important information on all these efforts. We, as representatives of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the lead institute for BACPAC, thank the staff from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the other institutes, centers, and offices (National Institute on Aging, National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Institute on Minority Health and Disparities, National Center for Complementary and Integrative Health, Office of Behavioral and Social Sciences Research, and Office of Research on Women’s Health) that have joined in this effort. We especially salute all the investigators who have worked diligently and cooperatively to move research in back pain forward. The project held together despite the COVID-19 pandemic, largely through the efforts of the investigators to maintain lines of communication. The landscape has also shifted, with a new